This could possibly be the largest week for biotech IPOs in years — even when the federal government stays shuttered briefly.
Authorities funding lapsed this previous Saturday, sparking a partial authorities shutdown that has closed businesses not deemed important for public security and nationwide safety. The record of closed businesses consists of the Securities and Alternate Fee, which should log off on an IPO submitting earlier than an organization can go public.
The shutdown could possibly be transient. Home Speaker Mike Johnson mentioned on Meet the Press that he expects the Senate-passed funding invoice will go to a vote within the Home of Representatives by Tuesday. However till the federal government reopens, the SEC’s operations plan states the company is not going to course of new or pending registration statements.
Throughout all sectors, as many as eight corporations are lined up for IPOs this week, based on IPO analysis agency Renaissance Capital. If all eight value their choices this week, it could mark probably the most energetic week for IPOs since 2021, Renaissance mentioned. 4 on this record are biotech corporations: Eikon Therapeutics, Veradermics, AgomAb Therapeutics, Spyglass Pharma. These biotechs might nonetheless go public even with the SEC closed. Earlier than the federal government shut down, the company late Friday filed a discover of effectiveness for every one. The submitting is an SEC declaration {that a} registration assertion has met all the company’s authorized and regulatory necessities, clearing the corporate to proceed with an IPO.
Although 2025 IPO exercise didn’t attain the heights many had hoped, the entire variety of new public corporations nonetheless marked a four-year excessive, based on Renaissance’s 2026 IPO outlook report. The agency counted 202 corporations that went public in 2025, elevating $44 billion. These figures proceed the upward development in IPOs since a drop-off after the 2021 peak, when 397 IPOs raised $142.4 billion, based on the report.
Stabilizing macroeconomic circumstances after tariff volatility in 2025 together with cooling inflation and declining rates of interest are among the many components that Renaissance sees driving IPO exercise this yr. The agency additionally mentioned there’s a sturdy backlog of corporations ready to go public, lots of them near-term IPO candidates. Renaissance tasks 200 to 230 IPOs throughout all sectors this yr will elevate between $40 billion and $60 billion.
Wealthy Segal, a accomplice at Cooley, mentioned the sturdy IPO markets of 2020 and 2021 was not regular, and he doesn’t assume the expectation ought to be that exercise will return to these ranges. Cooley sees a progressive improve in IPOs for 2026. Segal added that there’s typically IPO exercise across the J.P. Morgan Healthcare Convention every January. Aktis Oncology had the primary biotech IPO of 2026debuting on the Nasdaq simply forward of the convention.
Eikon, Veradermics, SpyGlass, and AgomAb all timed the filings of their registration statements to coincide with the JPM convention. Final week, these corporations up to date their filings with preliminary monetary phrases for his or her deliberate IPOs. Segal mentioned that after the brand new yr begins, many buyers need to see the instant prior yr financials. Some corporations could push out an IPO date additional to allow them to present these information.
There’s one other strategy to go public throughout a authorities shutdown. Underneath Part 8(a) of the Securities Act, a registration assertion turns into efficient 20 days after it’s filed. Shashi Khiani, shareholder within the securities and company finance observe at Polsinelli, notes that the majority corporations don’t need to go public this fashion so that they embody an modification to the submitting that delays effectiveness till the corporate is notified by the SEC. That’s as a result of if an organization begins promoting shares and the SEC later finds an issue with the prospectus, the corporate might face enforcement motion from the regulator and lawsuits from shareholders. Firms that pursue this path to the general public markets are probably additional alongside within the SEC evaluation of the prospectus, Khiani mentioned.
“Firms who’ve been by means of a few rounds with the SEC now, the place they’ve a modicum of consolation that they’ve addressed the SEC’s feedback and there’s no situation, I believe they could be stronger candidates or extra probably to make use of this selection,” he defined.
Due to the authorized dangers, Khiani has been advising purchasers to not go public utilizing the Part 8(a) rule. However two biotechs did use this rule to go public in the course of the 43-day authorities shutdown final fall: MapLight Therapeutics and Evommune. Cooley suggested each biotechs on their IPOs, although Segal was not concerned in both one. Talking typically, Segal mentioned utilizing Part 8(a) to go public just isn’t one thing an organization would do when the federal government is open.
“It’s positively a tactic of final resort,” he mentioned. “I don’t assume anyone’s doing it as the primary choice, but when the federal government continues to close down, we’ll probably proceed to see different corporations do that. However I believe it’s going to be small numbers. If the federal government’s open and functioning, folks will do it the common approach.”
Not less than one biotech firm has joined the general public markets in the course of the present authorities shutdown. Polaryx Therapeutics went public Monday by way of a direct itemizing, during which firm insiders promote their shares on to the general public with out involving underwriters. Going public this fashion nonetheless requires the SEC to log off on the registration assertion. The SEC gave the inexperienced mild to the Polaryx submitting and issued a discover of effectiveness final week, earlier than the shutdown.
In contrast to a conventional IPO, a direct itemizing doesn’t elevate new cash for a corporation. Which means Polaryx nonetheless wants to search out capital for its medical trial plans. Lead Polaryx drug candidate PLX-200 is on observe to enter a Section 2 examine within the first half of this yr testing the drug in uncommon lysosomal storage issues. In line with Polaryx’s prospectusthe corporate’s money place was $5.7 million on the finish of the third quarter of 2025. The submitting doesn’t supply estimates for the medical trial prices, however states that Polyaryx expects its capital will final solely by means of the third quarter of this yr.
Photograph: Angela Weiss/AFP, by way of Getty Photographs
